MASAI RCT shows Transpara safe for workload reduction Summary

Smart AI for early breast cancer detection and diagnosis

We focus on improving breast cancer survival rates by detecting cancers earlier and making treatment more effective and less intense.

FDA cleared for use on all major 2D and 3D mammography systems. 

LEARN ABOUT OUR CLINICAL EVIDENCE HERE

The ScreenPoint Experience

Supporting you through your AI journey

Why Transpara?

Trusted in more than 30 countries

Trusted in more than 30 countries

FDA cleared and CE marked for 2D and 3D mammography

FDA cleared and CE marked for 2D and 3D mammography

The most independent peer reviewed publications in breast AI

The most independent peer reviewed publications in breast AI

Proven multivendor compatibility

Proven multivendor compatibility

Integrated with most workstations

Integrated with most workstations

Experience the benefit of our continuously evolving deep learning algorithm

Experience the benefit of our continuously evolving deep learning algorithm

Peer Reviewed Publications

Accuracy.
Workload Reduction.
Results.

"Transpara has the potential to detect specific cancers earlier. I can think of 1-2 recent cases with calcifications, where Transpara detected a cancer earlier that was not easily visible on a mammogram."

Dr Brian Englander

Dr Englander, Robert E. Campbell Professor of Clinical Radiology, Perelman School of Medicine Chairman, Department of Radiology, Pennsylvania Hospital Penn Center for Global Health Scholar

"Transpara increases my confidence and efficiency going through a screening mammography session. I have more focus especially with the higher risk cases thanks to their Intuitive Triage software."

Dr Roger Yang

MD, FACR, University Radiology Group

"I use Transpara all the time, and won't read another 3D mammogram without it. The product fits seamlessly into our workflow, and we have found over time it has increased our mammography workflow. Thanks to the technology's score card we are also able to focus on those high risk patients first, and get those patients the care they may need faster."

Dr Daniel Gurell

Vice President and Associate Medical Director at University Diagnostic Medical Imaging P.C.USA

“Transpara may allow discriminating studies, which require more attention and selection of those, which may be handled with single reading for example. It may thus contribute significantly to both risk adapted screening and optimum assignment of resources."

Professor Sylvia H Heywang-Köbrunner

Radiologist, Head of the Referenzzentrum Mammographie Munich, Germany

"We are at the forefront of one of the first prospective studies with Transpara. As we will implement Transpara in a real-life screening setting in Ostergotland County, we aim to improve the quality of the breast cancer screening program while at the same time safely reduce the workload of breast radiologists."

Håkan Gustafsson

Deputy Director CMIV, AI Coordinator at Region Östergötland

The Transpara Process

The Transpara Process
Client scan

Client scan

Client undergoes mammogram

Analyze scan

Analyze scan

Transpara analyses mammogram scan

Reading with Transpara

Reading with Transpara

Radiologist reads with support from Transpara, increasing confidence in decision

Result

Make more accurate and consistent decisions

News

Radiologist resource Media coverage


Dr. Margolies (MAB Member, Transpara User) on CBS Evening News

Artificial Intelligence (AI) in medicine is different than the AI used on common layperson applications. In medicine, users of AI

Read more

Announcement


ScreenPoint Medical Hits New Milestones

World’s Leading Breast AI Software, Transpara Surpasses 5 Million Mammograms and 1 Million Tomosynthesis Studies Analyzed to Support Radiologists Reading

Read more

Announcement


ScreenPoint Medical Showcases Global Momentum for Transpara(R) Breast AI at EUSOBI

The Most Clinically Validated Breast AI Featured in 4 Significant Peer-Reviewed Studies in Past 6 Months, Better Workflow to Increase

Read more

Media coverage


ScreenPoint and Transpara in the News!

Our Nijmegen office was visited by a Netherlands-based news crew the week of August 1. What was the big news?

Read more

Announcement


Transpara® Helps Radiologists Detect More Cancers while Safely Reducing Workload

Randomized Controlled Trial for Breast AI as Second Reader: Preliminary Results Published in The Lancet Oncology   Transpara®-assisted workflow helps

Read more

Announcement Clinical evidence


First randomised trial finds AI-supported mammography screening is safe and almost halved radiologist workload

Press Release From Lancet Oncology: The AI in use is Transpara First randomised trial finds AI-supported mammography screening is safe

Read more